Imagine a world where a silent killer lurks within millions, often undetected until it's too late. That's the grim reality of heart valve disease, a condition affecting over 28 million people globally, with numbers rising steadily. In the U.S. alone, it claims more than 60,000 lives annually, yet many remain unaware of its symptoms or delay seeking treatment. But here's the shocking truth: this devastating disease is often treatable if caught early. The American Heart Association is determined to change this narrative.
And this is where the battle begins. To combat the growing threat of heart valve disease, the American Heart Association, a pioneering force in global health transformation, is launching a groundbreaking nationwide initiative. This ambitious project, aptly named the Heart Valve Initiative, aims to revolutionize patient care by integrating science, education, and systemic improvements. By harmonizing efforts in patient and professional education, care systems, and quality enhancement, the Association seeks to significantly improve patient outcomes and healthcare standards.
The initiative will focus on early detection, swift treatment, and evidence-based care delivery. But here's where it gets controversial: How can we ensure that healthcare systems and clinicians prioritize heart valve disease amidst competing health concerns? The Heart Valve Initiative addresses this by introducing hospital certification programs, advanced professional education, and patient engagement tools, all designed to elevate care across the entire patient journey.
“The American Heart Association is uniquely positioned to spearhead this comprehensive initiative, ensuring timely diagnosis, appropriate treatment, and ultimately, longer, healthier lives for those with valve disease,” said Mariell Jessup, M.D., FAHA, Chief Science and Medical Officer. “Our priority is to create a seamless care system that eliminates unnecessary delays from diagnosis to treatment. We urge healthcare professionals to act decisively: listen attentively, diagnose promptly, and treat proactively.”
Here’s the part most people miss: The Heart Valve Initiative is made possible through the support of founding sponsor Edwards Lifesciences, building on their existing work in aortic stenosis (AS), a prevalent and severe form of heart valve disease. Their Target: Aortic Stenosis™ program utilizes a data registry to enhance patient care from symptom onset to treatment and management. Edwards Lifesciences’ commitment extends beyond AS, aiming to transform care for all heart valve disease patients.
Heart valve disease affects one in 40 people in the U.S., with risks escalating significantly after age 65. But here’s a thought-provoking question: Are we doing enough to raise awareness and educate the public about this silent threat? Todd J. Brinton, Chief Scientific Officer at Edwards Lifesciences, emphasizes, “Over six decades of treating structural heart disease, we’ve seen too many cases go undiagnosed until it’s too late. Through innovations and initiatives like the Heart Valve Initiative, we’re committed to changing this by equipping healthcare professionals and patients with the tools to recognize symptoms early, engage in timely care, and save lives.”
Over the next five years, the initiative will:
- Enhance adherence to guideline-based care for heart valve diseases, starting with AS and expanding to other forms.
- Broaden data collection in the Target: Aortic Stenosis registry to include asymptomatic and moderate AS cases.
- Develop a guideline-based heart valve certification program for hospitals.
- Promote public reporting and hospital recognition to drive high-quality care.
- Provide multimedia education for healthcare professionals and patients.
- Launch a national awareness campaign to educate the public and empower informed care decisions.
Key clinical metrics will include timely diagnosis and management of severe and asymptomatic aortic stenosis, echocardiographic assessment quality, and appropriate referrals for follow-up care. In addition to Edwards Lifesciences, the initiative is supported by Kardigan.
Now, we want to hear from you: Do you think enough is being done to address heart valve disease? What steps can individuals and communities take to raise awareness and improve early detection? Share your thoughts in the comments below.
For more information, visit the following resources:
- Aortic Stenosis Fact Sheet
- American Heart Association Support Network
- Follow AHA/ASA news on X @HeartNews
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. For over a century, we’ve been a leading source of health information, supported by 35 million global volunteers. We fund groundbreaking research, advocate for public health, and provide critical resources to combat cardiovascular disease and stroke. Through science, policy, and care innovations, we strive to advance health and transform lives daily. Connect with us on heart.org, Facebook, X, or call 1-800-AHA-USA1.
For Media Inquiries: 214-706-1173 | Michelle Rosenfeld, Michelle.Rosenfeld@heart.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721) | heart.org and stroke.org
References:
1. Martin SS, et al. 2025 Heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. Published online January 27, 2025.
2. Screen Heart Valve Disease
